Switch theme
Sign up to access all valuation multiples
Airway Medix SA focuses on research, development and commercialization of devices for single use in mechanically ventilated patients at Intensive Care Units as well as in patients with life-threatening and anaesthesiologic wards. The company's products include Closed Suction System, Oral Care System and Cuff Pressure Regulator.
2013
8
LTM Revenue n/a
LTM EBITDA n/a
$9.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Airway Medix has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Airway Medix achieved revenue of $3K and an EBITDA of -$0.3M.
Airway Medix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Airway Medix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $25K | $3K | XXX | XXX | XXX |
| Gross Profit | $2K | $25K | XXX | XXX | XXX |
| Gross Margin | 6% | 792% | XXX | XXX | XXX |
| EBITDA | -$9.6M | -$0.3M | XXX | XXX | XXX |
| EBITDA Margin | -37889% | -10250% | XXX | XXX | XXX |
| Net Profit | -$1.9M | -$10.1M | XXX | XXX | XXX |
| Net Margin | -7415% | -315950% | XXX | XXX | XXX |
| Net Debt | $3.5M | $3.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Airway Medix's stock price is PLN 0 (or $0).
Airway Medix has current market cap of PLN 19.3M (or $5.1M), and EV of PLN 35.0M (or $9.3M).
See Airway Medix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.3M | $5.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Airway Medix has market cap of $5.1M and EV of $9.3M.
Airway Medix's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Airway Medix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Airway Medix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.3M | XXX | XXX | XXX |
| EV/Revenue | 2916.1x | XXX | XXX | XXX |
| EV/EBITDA | -28.4x | XXX | XXX | XXX |
| P/E | -5.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAirway Medix's NTM/LTM revenue growth is n/a
Airway Medix's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged n/a for the same period.
Over next 12 months, Airway Medix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Airway Medix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Airway Medix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -87% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -97% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 208% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Airway Medix acquired XXX companies to date.
Last acquisition by Airway Medix was XXXXXXXX, XXXXX XXXXX XXXXXX . Airway Medix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Airway Medix founded? | Airway Medix was founded in 2013. |
| Where is Airway Medix headquartered? | Airway Medix is headquartered in Poland. |
| How many employees does Airway Medix have? | As of today, Airway Medix has 8 employees. |
| Is Airway Medix publicy listed? | Yes, Airway Medix is a public company listed on WAR. |
| What is the stock symbol of Airway Medix? | Airway Medix trades under AWM ticker. |
| When did Airway Medix go public? | Airway Medix went public in 2014. |
| Who are competitors of Airway Medix? | Similar companies to Airway Medix include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Airway Medix? | Airway Medix's current market cap is $5.1M |
| What is the current revenue growth of Airway Medix? | Airway Medix revenue growth between 2023 and 2024 was -87%. |
| Is Airway Medix profitable? | Yes, Airway Medix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
